Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

By G. von Minckwitz, M. Untch, J. Blohmer, S. Costa, H. Eidtmann, Peter A. Fasching, B. Gerber, W. Eiermann, J. Hilfrich, J. Huober and 7 more. Journal of Clinical Oncology, 2012

2,412 citations recorded by the source corpus.

Subfields: Cancer Research, Pathology and Forensic Medicine, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/2fc0244cc57d6aeb54a7c6ad9f4ba145b85d7b61

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Aleix Prat
2. William Y. Kim
3. E. Gibb

In Pathology and Forensic Medicine

1. Aleix Prat
2. Ingrid A. Mayer

Citations in the corpus

• Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes (2013, background): “In previous studies, 20-30% of patients with TNBC achieved pathological complete response (pCR) neoadjuvant chemotherapy, and pCR was strongly associated with prolonged overall survival (OS) and event-free survival (4-7).”
• Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 (2013, neutral): “negative disease [55].”
• NEW STRATEGIES FOR TRIPLE NEGATIVE BREAST CANCER – DECIPHERING THE HETEROGENEITY (2014, background): “TNBC who do not achieve a pCR after anthracycline and taxane–based neoadjuvant chemotherapy will have a recurrencewithin 36months (48).”
• Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis (2020, neutral): “A pooled analysis by the German Breast Group based on 6,377 patients receiving neoadjuvant anthracycline-taxane–based chemotherapy in seven randomized trials suggested pCR is a suitable surrogate endpoint of recurrence for patients with luminal B/HER2-negative, HER2-positive (nonluminal), and TN dis”
• An overview of triple-negative breast cancer (2016, background): “The authors concluded that pCR should be conservatively defined as ypT0 ypN0 excluding ductal carcinoma in situ, and that pCR is an effective surrogate for survival for luminal B (HER2-negative), HER2-positive (non-luminal) and TNBC tumors, but not for luminal A or luminal B/HER2-positive tumors [82”
• Clinical implications of the intrinsic molecular subtypes of breast cancer. (2015, background): “This hypothesis is further sustained by the fact that pCR is not predictive of survival outcome in IHC-Luminal A tumours [53] and in patients with HRþ/HER2 /lowgrade [55], but it is predictive of outcome in IHC-Luminal B/HER2negative [53] and in HRþ/HER2 /high-grade [55].”
• Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. (2017, result): “However, our findings resemble those in breast cancer, where pathological response relates to outcome in some, but not all, molecular subtypes [20].”
• Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. (2017, neutral): “9 72 (33) 79 (30) 109 (32) 260 (32) 23 (17) 28 (14) 31 (15) 342 (30) $ 30 71 (32) 96 (37) 151 (44) 318 (39) 19 (14) 40 (20) 37 (18) 414 (36) NA 4 (2) 3 (1) 9 (3) 16 (2) 67 (51) 1 (0) 1 (0) 85 (7) Diabetes No 195 (88) 236 (89) 293 (86) 724 (88) 95 (72) 93 (46) 84 (41) 996 (86) Yes 24 (12) 26 (10) 46 ”